VT 5 laps ahead in a 6 lap race.
"Zhittya Genesis Medicine is CardioVascular Biotherapeutics (Venturis Therapeutics) only competitor in the development of FGF-1. Zhittya Genesis Medicine was founded by the former CEO and founder of CVBT, Dan Montano. Zhittya Genesis Medicine has since soared (into oblivion) to the top since he left CVBT in 2014."
Zhittya isn't a competitor of VT. Zhittya is what is referred to in Las Vegas as, SMOKE & MIRRORS.
"Under the Marketplace Exclusivity, the first company to obtain approval gets an effective monopoly for 10 years. With Zhittya Genesis Medicine (ZGM) indubitably ahead of Venturis Therapeutics by about six years, it is clear who will be the first to monopolize the FGF-1 industry."
Zhittya is stumbling around in a Phase 1 trial in Mexico. They have treated ZERO patients. VT have a Phase 2 CAD trial ongoing & a Phase 2b/3 pivotal trials. In other words VT is around 5 laps ahead in a 6 lap race.
"Zhittya Genesis Medicine and Venturis/CVBT are the only two companies in the race to commercialize FGF-1. Clearly Zhittya Genesis Medicine is far ahead of Venturis in the race as their announcements clearly state that they now have a large batch of FGF-1 at their disposal, have started numerous clinical trials such as in Parkinson's Disease and ALS, have had countless webinars whose social media campaign has touched tens of millions of people, with their subscriber list at tens of thousands."
Countless webinars mean diddly squat with the US FDA. To reiterate VT is around 5 laps ahead in a 6 lap race.
"CVBT/Venturis has now lost Myerson, CVBT has now lost yet another major court battle, Venturis has now lost the majority of their administration. What do we have? There are no experts running Venturis Therapeutics, those experts fled the company after they testified in court that CVBT was lying!"
Again, completely erroneous. Myerson was fired by VT years ago. Refer to the VT presentation where it lists the comprehensive nature of the CVBT team. Anyone who wants the presentation can contact Grant Gordon (my source) at ggordon@venturistherapeutics.com. Needless to say the naysayers have no up to date information on VT as VT has deliberately flown under the RADAR for years which is changing as I write this.
With Daniel C. Montano's $1 million dollar judgement against CVBT/Venturis Therapeutics (WHICH CVBT/VENTURIS HAS NO OFFSET) it is clear that Dan Montano will be coming after Cardiovascular Biotherapeutics.
VT has offset due to Calvin Wallen assigning his $2.5 million judgement against Dan Montano to VT. This means that Dan Montano now owes VT $1.7 million.
Every Cardiovascular Biotherapeutics/Venturis Therapeutics shareholder has to keep up with Zhittya Genesis Medicine because they are our only competition! Our competition is leaving us in the dust, without a doubt they are six years ahead of us!
To reiterate (yet again) VT is around 5 laps ahead in a 6 lap race.
Ultimately I must ask, Zhittya Genesis Medicine has proven that in 6 years a lot of progress can be made. Where is CVBT/Venturis Therapeutics progress? We have made no drug, we have had no shareholders meeting, we have done nothing but lose court battle after court battle in the last half decade. We are losing. When will our CVBT management respond?
VT has drug & are in pivotal trials with the US FDA. Zhittya is in a Phase 1 trial in Mexico, not under FDA auspices.
Every CVBT shareholder should care.
Every VT shareholder does care and are pleased to be on the equivalent of a super yacht as opposed to SS Titanic (Dan Montano/Zhittya).
The one area that Dan Montano is miles ahead of VT & VT management is the number of failed/bankrupted businesses he’s been involved in scuppering. Something in the order of 20 failed businesses over the past 30 years. In addition Dan Montano is in personal bankruptcy. A SERIAL FAILURE.
VT has a comprehensive IP portfolio. Zhittya have nada, not one patent to its name. The failed CEO, Dan Montano, actually believes that in biotechnology IP is worthless. That alone tells you all you need to know about the failed CEO.
News 
Market Data 
Discover 
